International Niemann–Pick Disease Alliance

Updates

  1. ASMD NP-B Enzyme Therapy: Luiz Henrique

    Just last week we happily reported that three year old Isadora, had became the first patient of her age to receive enzyme therapy for ASMD Niemann-Pick disease type B. This tremendous news filled everyone connected to the INPDA with a sense...

    Read story
  2. Orphazyme: Update #12 on the AIDNPC Clinical Programme

    Update #12 on the AIDNPC clinical programme (arimoclomol in treatment of Niemann-Pick disease type C)  (Available for download in English, French, German, Italian, Polish, Spanish) Conference call with patient organizations (22 DECEMBER ’16) SUMMARY 002 Study: Recruitment into the...

    Read story
  3. The First Three Year Old Patient to Receive Enzyme Therapy for Niemann-Pick Type B

    A constant smile and strong personality are just two traits of Isadora, a Brazilian girl who has became the first three year old in the world to receive enzyme therapy for Niemann-Pick type B disease. Upon hearing this news...

    Read story
  4. CTD Holdings Files Clinical Trial Application with Italian Drug Agency to Continue Advancing Trappsol(R) Cyclo(TM) Drug Development Program to Treat Niemann-Pick Disease Type C

    Marketwired Dec 21, 2016 8:00 AM ALACHUA, FL–(Marketwired – December 21, 2016) – CTD Holdings, Inc.(CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced its filing of a Clinical Trial Application (CTA) with...

    Read story
  5. Sanofi Genzyme: Pivotal Phase 2/3 Trial of Olipudase Alfa for Adult Patients with Acid Sphingomyelinase Deficiency to Begin in the UK

    Pivotal Phase 2/3 Trial of Olipudase Alfa for Adult Patients with Acid Sphingomyelinase Deficiency (Niemann-Pick Disease Type B) to Begin in the UK  Oxford, UK – 3 November, 2016 – Sanofi Genzyme, the specialty care global business unit of...

    Read story
  6. Jim Green: CNPDA Visit

    There is so much going on as of late; with various clinical trials beginning and/or expanding, new companies joining the fight against Niemann-Pick disease (Perlara and Novartis), and the partnership of Quinn Madeline and Baby Genes in order to create the first diagnostic carrier...

    Read story
  7. Clinical Trial Update: Orphazyme expands NPC study to three sites in the USA

    Clinical Trial Update: Orphazyme expands NPC study to three sites in the USA ( Download Here) Orphazyme’s clinical programme AIDNPC, investigating the orally administered small molecule arimoclomol as a treatment for Niemann-Pick disease type C, is close to opening...

    Read story
  8. Orphazyme: Update #11 on the AIDNPC Clinical Programme

    Update #11 on the AIDNPC Clinical Programme (arimoclomol in treatment of Niemann-Pick disease type C) You can download the article here                                    ...

    Read story
  9. “No more tiredness – I look forward to it!” Rani Voncxz

    HLN.BE REGIO The days have been tiring recently for the family from Tessenderlo, but they endured the biweekly trips to Amsterdam for the tests with a smile! Not exactly surprising when you learn that this year marks sixteen years...

    Read story
  10. The Quinn Madeline Foundation Establishes First-Ever Niemann-Pick Diagnostic Carrier Screening Programme

    You can download this press release here The Quinn Madeleine Foundation establishes first-ever Niemann-Pick diagnostic carrier screening program Aiming to eradicate fatal ASMD, The Quinn Madeleine Foundation has partnered with Baby Genes to create a diagnostic carrier screening program...

    Read story

Join the Registry

Calling all patients and carers! We've created a global registry of all NPD patients - if you're not enrolled yet, join us now...

The Impact of NPC

The global community tell their stories...